Tirzepatide and Sleep Apnea: SURMOUNT-OSA in Plain English

Tirzepatide sleep apnea trials have produced some of the most striking results in obesity medicine in years — not because of how much weight participants lost (though that was impressive too), but because of how significantly their breathing improved at night. The SURMOUNT-OSA program asked a pointed question: if you treat the obesity, does the sleep apnea follow? The answer was mostly yes, with some genuinely interesting nuance about what's driving the improvement.

Here's what the data actually showed and what it means if you have obstructive sleep apnea (OSA) and are considering tirzepatide.

What SURMOUNT-OSA was studying

Obstructive sleep apnea is heavily linked to obesity. Excess fat deposits around the neck and throat narrow the upper airway, making it collapse during sleep. Each collapse is an "apnea event" — a brief pause in breathing — and they're measured as the apnea-hypopnea index (AHI): events per hour of sleep.

• AHI < 5: normal
• AHI 5–14: mild OSA
• AHI 15–29: moderate OSA
• AHI ≥ 30: severe OSA

Most people in SURMOUNT-OSA had severe OSA at baseline, with average AHI scores well above 30 events per hour. The hypothesis was simple: tirzepatide reduces body weight substantially, and less weight around the airway should mean fewer apnea events.

SURMOUNT-OSA ran as two parallel 52-week Phase 3 trials, both in adults with obesity (BMI ≥ 30) and moderate-to-severe OSA (AHI ≥ 15):

• Trial 1 enrolled participants who chose not to use PAP therapy (CPAP/BiPAP) during the study
• Trial 2 enrolled participants already on PAP therapy who continued using it

The split was deliberate: it let researchers measure whether tirzepatide could improve OSA without a PAP device running in parallel, and whether it could add benefit on top of PAP.

What the AHI numbers showed

The primary endpoint in both trials was change in AHI from baseline at 52 weeks. The results were published in The New England Journal of Medicine in 2024.

In Trial 1 (no PAP): tirzepatide produced roughly a 55–60% relative reduction in AHI compared with about a 10–15% reduction on placebo. In absolute terms, tirzepatide cut AHI by more than 25 events per hour on average — enough to shift most participants from the severe category into moderate or mild.

In Trial 2 (already on PAP): AHI reductions were similar in magnitude. Adding tirzepatide on top of existing PAP therapy produced additional meaningful reductions — confirming the drug was doing something beyond what the device alone was achieving.

Both differences were highly statistically significant, and both met pre-specified criteria for clinical meaningfulness. A proportion of tirzepatide participants in Trial 1 achieved complete remission — AHI below 5 events per hour — without any PAP device.

Weight loss across both trials was approximately 20% of body weight at 52 weeks, consistent with the broader SURMOUNT program data.

The central question: weight-mediated or independent?

This is where it gets more interesting. Most of the OSA improvement almost certainly runs through weight loss — less fat around the airway, less obstruction. That's the mechanistic story you'd expect.

But a few observations in the data hint at something additional:

• The AHI reductions appeared somewhat larger than what's typically predicted from the degree of weight loss alone, based on historical observational data
• In subgroup analyses, AHI improvements were seen even in participants with smaller weight losses
• GLP-1 receptors are expressed in upper airway motor neurons in animal models, raising the possibility of a direct neuromuscular effect on pharyngeal tone

None of this is definitive. The trials weren't designed to tease apart weight-mediated from weight-independent effects — that would require a different study design where weight loss is held constant. What we can say is that the weight loss is the primary driver, and that any additional direct effect (if it exists) is difficult to quantify from the current data.

The more practically important point: whether the mechanism is direct or indirect, tirzepatide's OSA results are clinically meaningful in a way that medications haven't typically achieved before.

What the FDA did with this data

In December 2024, the FDA approved Zepbound (tirzepatide) for a new indication: adjunctive treatment for moderate-to-severe obstructive sleep apnea in adults with obesity. This made Zepbound the first prescription obesity medication ever approved specifically for OSA.

The approved indication requires:

• Moderate-to-severe OSA (AHI ≥ 15)
• Obesity (BMI ≥ 30 kg/m²)
• Use alongside a reduced-calorie diet and increased physical activity

It's approved as an adjunct treatment — not a replacement for CPAP or other established OSA therapies. Your sleep specialist and prescribing clinician should guide the conversation about whether tirzepatide replaces, supplements, or stands alone alongside your existing OSA management.

Who this is most relevant for

The SURMOUNT-OSA population had a very specific profile: severe OSA + significant obesity + willingness to inject weekly. If you check those boxes, the trial results are directly applicable to you.

A few scenarios where the OSA indication particularly matters:

What it doesn't tell us

• Long-term durability: the trials ran 52 weeks. What happens to AHI after 2–3 years, or if tirzepatide is discontinued? Early data from similar GLP-1 programs suggests that benefits reverse with weight regain, which is consistent with the weight-mediated mechanism. More data is needed.
• Mild OSA: the trials required AHI ≥ 15. Whether tirzepatide meaningfully benefits mild OSA (AHI 5–14) isn't established.
• Non-obese OSA: if your OSA isn't related to obesity, the weight-loss mechanism doesn't apply, and the OSA indication is irrelevant for you.
• Head-to-head with CPAP: CPAP remains the gold standard for treating OSA. Tirzepatide hasn't been directly compared to CPAP in an RCT.

Practical takeaways

If you have moderate-to-severe OSA and obesity, tirzepatide's SURMOUNT-OSA results are worth a conversation with both your prescribing clinician and your sleep specialist. A few practical points:

1. Don't stop CPAP before talking to your doctor. Even if AHI improves dramatically, formal re-testing (typically a home sleep test or in-lab study) is needed to document the improvement before changing your treatment plan.
2. AHI improvement typically follows weight loss — expect the biggest changes after 3–6 months on the maintenance dose, not in the first few weeks.
3. Insurance coding matters. The Zepbound OSA indication uses ICD-10 code G47.33 (obstructive sleep apnea, adult). If you've been denied under obesity criteria, your prescriber may have better luck with the OSA diagnosis code.

For more on what to expect from tirzepatide overall, see our tirzepatide guide and the SURMOUNT trial results. If OSA-related fatigue is part of your picture, the fatigue side-effects page covers the intersection between GLP-1 treatment and daytime energy.

Related reading

• Tirzepatide complete guide
• SURMOUNT trial results explained
• Tirzepatide vs semaglutide
• GLP-1 side effects overview